Bruce Freeman, PHD
Bruce Freeman, PhD is a biochemist and pharmacologist who investigates eukaryotic cell production and actions of reactive inflammatory and signal transduction mediators (e.g., superoxide, nitric oxide, peroxynitrite, electrophilic lipids). He is presently the Irwin Fridovich Professor and Chairman of the Department of Pharmacology and Chemical Biology at the University of Pittsburgh School of Medicine and is a member of Pitt’s Vascular Medicine Institute and Cancer Institute.

His laboratory team has made seminal discoveries related to the tissue production and target molecule reactions of reactive inflammatory mediators, which in turn reveal the fundamental process of redox reaction-regulated cell signaling. These insights have led to Dr. Freeman’s identification of new drug strategies for treating metabolic diseases, fibrosis and acute/chronic inflammatory disorders. His team pioneered the concept that nitric oxide has cell signaling and pathogenic actions modulated by a reaction with superoxide, yielding the oxidizing and nitrating species peroxynitrite. Their studies of heme peroxidases have also shown additional pathways leading to biomolecule oxidation and nitration. Of relevance to Complexa, his laboratory also discovered that metabolic and inflammatory reactions of unsaturated fatty acids yield electrophilic nitro and keto derivatives of unsaturated fatty acids, products that manifest potent anti-inflammatory and tissue-protective signaling actions. His discovery of nitric oxide reactions with various oxidases and peroxidases has also revealed clinically-significant mechanisms of catalytic nitric oxide consumption that occur during inflammation and metabolic syndrome. His mass spectrometry-based observations of peroxynitrite, peroxidase and electrophilic fatty acid-induced post-translational protein modifications further underscore the significance of redox reactions in regulating cell and organ function. This work has led to numerous issued patents and >250 peer-reviewed publications in high- impact basic science and clinical journals.

Previously, Dr. Freeman was Professor of Anesthesiology, Biochemistry and Molecular Genetics and Environmental Health Sciences at the University of Alabama at Birmingham (UAB). He was also Vice Chair for Research in the Department of Anesthesiology and Director of the UAB Center for Free Radical Biology. Prior to service at UAB, he trained at the University of California and Duke University, where he also served on the faculty. He has been the recipient of a number of honors, including being named a Fulbright Research Scholar and serving as an invited lecturer at Nobel Forums. He and his lab team have secured more than $40 million in extramural funding to support their research activities. Dr. Freeman’s academic leadership has also propelled students, fellows and faculty colleagues into prominent basic science, clinical investigator and pharmaceutical industry positions.

Margaret Tarpey, M.D.
Dr. Tarpey is a Professor of Anesthesiology and Pharmacology at the University of Pittsburgh School of Medicine and brings a clinical dynamic to the founding scientists of Complexa. Her academic research interests in the reactions of nitric oxide and oxygen radicals in cardiovascular diseases, combined with her operating room and ICU-based clinical experience, make her a perfect fit as the company elucidates the clinical safety and mechanisms of action of Complexa’s proprietary compounds. Dr. Tarpey received a B.S. in Biochemistry from the University of California, Riverside, an M.S. in Physiology and Pharmacology from the University of California, San Diego and then went on to receive her medical training at Duke University. Dr. Tarpey then completed her residency and fellowship in Anesthesiology at the University of South Carolina and the University of Alabama at Birmingham, where she practiced medicine and conducted laboratory-based research.
Raymond A. Miller, Esq.
In addition to the scientific founders, Ray Miller played a critical role in Complexa’s founding by executing some of the company’s key intellectual property and helping to identify the business development team. Mr. Miller is a partner with the pre-eminent law firm of Pepper Hamilton, LLP and is the head of Pepper Hamilton’s Patent Group. Ray primarily focuses on biopharmaceuticals and has been involved in companies at every stage of financing. Ray is on the faculty of the BIO Boot Camp and guest lectures at Wharton Business School and Carnegie Mellon University on transactional intellectual property. Ray received a B.S. from the University of Akron, an M.A. from Princeton University and his J.D. from Case Western Reserve University School of Law.